CBSE Board Exam 2025 Live: Both CBSE Class 10 and 12 board exams were conducted ... The students coming back after writing their Business Studies paper of grade 12 were elated and at peace ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

VIR-5818, the only dual-masked HER2-targeting TCE in clinical trials, showed tumor shrinkage across various tumor types in 50% (10/20 ... cancer cells in the tumor microenvironment, minimizing ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Good morning, ladies and gentlemen, and thank you for standing by.

Good morning, and welcome, everyone, to Cellectis fourth quarter and full year 2024 business update and ... overcome their immunosuppressive tumor microenvironment. Preclinical data were presented ...

Good morning, everyone, and welcome to UroGen Pharma's fourth quarter and full year 2024 financial results and business update ... replication within the tumor microenvironment, features that ...

These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K.

CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma ... s pre-clinical studies and completed clinical ...

Texas’ upper elementary school students typically take civics, Texas history, and U.S. history to fulfill social studies requirements. Instead, upper-grade students ... In an October 10, 2023 ...

Background: Cluster of differentiation 74 (CD74) is found to be highly involved in the development of various types of cancers and could affect the activities of infiltrated cells in the tumor ...